Clinical trial · no report yet · Phase 3
OASIS-4
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
- NCT05587296 ↗
- Active not recruiting
- Bayer
- 27 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 14 | |
| YouTube | 8 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for an Additional up to 3.5 Years in Women With Hormone-receptor Positive Breast Cancer:
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Hot Flashes
- Interventions
- Elinzanetant (BAY3427080); Placebo
- Arms
- Elinzanetant (BAY3427080) · Experimental
- Placebo · Placebo comparator
- Enrollment
- 474
- Primary outcomes
- Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])
- Mean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)
- Sponsor
- Bayer
- Start
- Oct 14, 2022
- Primary completion
- Jan 29, 2024
- Results posted
- Yes
- Registry record
- NCT05587296 · updated Jul 9, 2026
Publications
linked from the registry- Cardoso F, Parke S, Brennan DJ, Briggs P, Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. N Engl J Med. 2025 Aug 21;393(8):753-763. doi: 10.1056/NEJMoa2415566. Epub 2025 Jun 2. PubMed 40454634